Study of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) for On-demand Treatment of Bleeding Episodes in Patients With Hemophilia A or B With Inhibitors
Clinical trial NCT02484638 · TERMINATED
Trial details
- NCT number
- NCT02484638
- Sponsor
- CSL Behring
- Status
- TERMINATED
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2015-07-23
- Primary completion
- 2018-03-28
- Enrollment
- 25
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.